Association of CX3CR1 Gene Polymorphisms with Fractalkine, Fractalkine Receptor, and C-Reactive Protein Levels in Patients with Kidney Failure
Open Access
- 23 February 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (4), 2202
- https://doi.org/10.3390/ijerph18042202
Abstract
Fractalkine (CX3CL1) is a chemokine that plays a significant role in inflammation, one of the pathophysiological processes underlying end-stage renal disease (ESRD). Genetic factors are significantly involved in cytokine expression and have been studied as potential risk factors for chronic kidney disease (CKD). Objectives: We aimed to elucidate the association of CX3CR1 gene polymorphisms rs3732378 and rs3732379 with the levels of CX3CL1, CX3CL1 receptor (CX3CR1), as well as C-reactive protein (CRP). Patients and methods: We enrolled 198 participants, including 106 patients with ESRD and 92 controls. Peripheral blood samples were collected from each patient for genetic (rs3732378 and rs3732379 polymorphisms) and immunoenzymatic (fractalkine, CX3CR1, CRP) tests. Results: CX3CR1 and CRP levels were higher in patients with ESRD than in controls (p < 0.05). Fractalkine levels were significantly higher in ESRD patients who were homozygous for the G allele of the rs3732378 polymorphism and for the C allele of the rs3732379 polymorphism than in homozygous controls. Moreover, carriers of these alleles among patients with ESRD had significantly higher CX3CR1 levels than controls. Conclusions: The G allele of the rs3732378 polymorphism and the C allele of the rs3732379 polymorphism of the CX3CR1 gene are associated with higher CX3CL1 and CX3CR1 levels. Our study suggests that CX3CR1 gene polymorphisms could be potentially involved in the pathogenesis of ESRD, but the study needs to be replicated in a larger population with a longitudinal follow-up study. Identification of genetic factors associated with inflammation in ESRD may contribute to the development of targeted gene therapies in the future.Funding Information
- Śląski Uniwersytet Medyczny (KNW-1-176/N/6/K)
This publication has 26 references indexed in Scilit:
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice GuidelineAnnals of Internal Medicine, 2013
- In vivo structure/function and expression analysis of the CX3C chemokine fractalkineBlood, 2011
- Oxidative stress and inflammation: Implications in uremia and hemodialysisClinical Biochemistry, 2011
- Inflamação na doença renal crônica: papel de citocinasBrazilian Journal of Nephrology, 2011
- Fractalkine/CX3CR1 and atherosclerosisClinica Chimica Acta; International Journal of Clinical Chemistry, 2011
- MALNUTRITION‐INFLAMMATION‐ATHEROSCLEROSIS SYNDROME IN PATIENTS WITH END‐STAGE RENAL DISEASEJournal of Renal Care, 2011
- Inflammation in end-stage renal disease: The hidden enemy (Review Article)Nephrology, 2006
- Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal InsufficiencyCirculation, 2003
- Fractalkine, a CX3C‐chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP‐1Immunology & Cell Biology, 2001
- Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery diseaseBlood, 2001